Gene Therapy in the Womb Is Inching Closer to Reality

Doctors can already detect abnormalities in the DNA of a developing human fetus.

By correcting these abnormalities before birth, a newborn will stand a better chance of a healthy Last week The main annual age of admin the American Society of Gene & Cell Therapy ore Los Angeles be to prevent disease before it happens.

Neurodevelopmental diseases often fit the bill of diseases that set in before birth and are hard to reverse afterward.

At the conference, a team from Yaleshared results in studies of monkeys showing that plastic-like nanoparticles will distribute into parts of the body, such as the kidney, that more conventional alternatives don’t.

It's still very early days for gene therapy in the womb.

Maternal immunity to the AAV9 virus often used to deliver gene therapy may foil in utero therapy in other cases.

More millions of dollars eeded t one nsure the safety of both fetus and parent.

First human trials are probably still 5 to 10 years away, says Peranteau. months >5 to 10 years Physicians _NxlGi">first Peranteau early days One AAV9< Bill Peranteau class="summaryFeed_highLightText__Nxl the Children's Hospital of Philadelphia ed_highLightText__NxlGi">Crispr Cas9 One two Borges one Peranteau hLightText__NxlGi">Turkish 2019 San Francisco the University of California, Beltrán Borges Zolgensma One FDA Palanki second three Crispr aryFeed_highLightText__NxlGi">first Alice Tarantal UC Davis PET Rohan Palanki Feed_highLightText__ MD l PhD >PET Peranteau Feed_highLightText__NxlGi">the California National Primate Center Davis the University of California, Yale Hurler Peranteau eau Neurodevelopmental Palanki Singapore26 weeks n class="summaryFeed_highLightText__NxlGi">the US Food and Drug Administration 17-fold Palanki Palanki